Ireland L S, Harrison D J, Neal G E, Hayes J D
Biomedical Research Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, Scotland, UK.
Biochem J. 1998 May 15;332 ( Pt 1)(Pt 1):21-34. doi: 10.1042/bj3320021.
The masking of charged amino or carboxy groups by N-phthalidylation and O-phthalidylation has been used to improve the absorption of many drugs, including ampicillin and 5-fluorouracil. Following absorption of such prodrugs, the phthalidyl group is hydrolysed to release 2-carboxybenzaldehyde (2-CBA) and the pharmaceutically active compound; in humans, 2-CBA is further metabolized to 2-hydroxymethylbenzoic acid by reduction of the aldehyde group. In the present work, the enzyme responsible for the reduction of 2-CBA in humans is identified as a homologue of rat aflatoxin B1-aldehyde reductase (rAFAR). This novel human aldo-keto reductase (AKR) has been cloned from a liver cDNA library, and together with the rat protein, establishes the AKR7 family of the AKR superfamily. Unlike its rat homologue, human AFAR (hAFAR) appears to be constitutively expressed in human liver, and is widely expressed in extrahepatic tissues. The deduced human and rat protein sequences share 78% identity and 87% similarity. Although the two AKR7 proteins are predicted to possess distinct secondary structural features which distinguish them from the prototypic AKR1 family of AKRs, the catalytic- and NADPH-binding residues appear to be conserved in both families. Certain of the predicted structural features of the AKR7 family members are shared with the AKR6 beta-subunits of voltage-gated K+-channels. In addition to reducing the dialdehydic form of aflatoxin B1-8,9-dihydrodiol, hAFAR shows high affinity for the gamma-aminobutyric acid metabolite succinic semialdehyde (SSA) which is structurally related to 2-CBA, suggesting that hAFAR could function as both a SSA reductase and a 2-CBA reductase in vivo. This hypothesis is supported in part by the finding that the major peak of 2-CBA reductase activity in human liver co-purifies with hAFAR protein.
通过N-邻苯二甲酰化和O-邻苯二甲酰化对带电荷的氨基或羧基进行掩蔽,已被用于改善包括氨苄西林和5-氟尿嘧啶在内的许多药物的吸收。吸收此类前药后,邻苯二甲酰基被水解,释放出2-羧基苯甲醛(2-CBA)和具有药理活性的化合物;在人体内,2-CBA通过醛基还原进一步代谢为2-羟甲基苯甲酸。在本研究中,负责人类体内2-CBA还原的酶被鉴定为大鼠黄曲霉毒素B1-醛还原酶(rAFAR)的同源物。这种新型的人类醛酮还原酶(AKR)已从肝脏cDNA文库中克隆出来,并与大鼠蛋白一起,确立了AKR超家族的AKR7家族。与大鼠同源物不同,人类AFAR(hAFAR)似乎在人类肝脏中组成性表达,并在肝外组织中广泛表达。推导的人类和大鼠蛋白质序列具有78%的同一性和87%的相似性。尽管预计这两种AKR7蛋白具有与AKR原型AKR1家族不同的二级结构特征,但催化和NADPH结合残基在两个家族中似乎都是保守的。AKR7家族成员的某些预测结构特征与电压门控K+通道的AKR6β亚基相同。除了还原黄曲霉毒素B1-8,9-二氢二醇的二醛形式外,hAFAR对与2-CBA结构相关的γ-氨基丁酸代谢物琥珀酸半醛(SSA)具有高亲和力,这表明hAFAR在体内可能同时作为SSA还原酶和2-CBA还原酶发挥作用。人类肝脏中2-CBA还原酶活性的主要峰与hAFAR蛋白共纯化这一发现部分支持了这一假设。